Analyst Expectations for Moderna's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 Wall Street analysts have provided ratings for Moderna (NASDAQ:MRNA) stock, with an average price target of $129.4, representing an implied upside from the current price of $78.73. The current average price target reflects a 25.85% decrease from the previous target of $174.50. Ratings are based on information from company calls, financial statements, and insider conversations. Analysts' opinions can vary, with 2 bullish, 1 somewhat bullish, and 2 indifferent ratings recently.
November 29, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's stock has a new average price target of $129.4, down from $174.50, with a mix of bullish and indifferent analyst ratings over the past 3 months.
The average price target suggests analysts believe MRNA has upside potential, which could lead to a positive short-term impact on the stock price. However, the decrease from the previous target and the mix of ratings indicate uncertainty, which may temper the stock's movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100